Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 242

1.

Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.

Schiffmann R, Floeter MK, Dambrosia JM, Gupta S, Moore DF, Sharabi Y, Khurana RK, Brady RO.

Muscle Nerve. 2003 Dec;28(6):703-10.

PMID:
14639584
[PubMed - indexed for MEDLINE]
2.

Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy.

Hilz MJ, Brys M, Marthol H, Stemper B, Dütsch M.

Neurology. 2004 Apr 13;62(7):1066-72.

PMID:
15079003
[PubMed - indexed for MEDLINE]
3.

Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.

Torvin Møller A, Winther Bach F, Feldt-Rasmussen U, Rasmussen A, Hasholt L, Lan H, Sommer C, Kølvraa S, Ballegaard M, Staehelin Jensen T.

Pain. 2009 Sep;145(1-2):237-45. doi: 10.1016/j.pain.2009.06.032. Epub 2009 Aug 7.

PMID:
19665302
[PubMed - indexed for MEDLINE]
4.

Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy.

Schiffmann R.

Acta Neurol Belg. 2006 Jun;106(2):61-5. Review.

PMID:
16898255
[PubMed - indexed for MEDLINE]
5.

Enzyme replacement therapy and intraepidermal innervation density in Fabry disease.

Schiffmann R, Hauer P, Freeman B, Ries M, Scott LJ, Polydefkis M, Brady RO, McArthur JC, Wagner K.

Muscle Nerve. 2006 Jul;34(1):53-6.

PMID:
16583374
[PubMed - indexed for MEDLINE]
6.

Small fiber dysfunction predominates in Fabry neuropathy.

Dütsch M, Marthol H, Stemper B, Brys M, Haendl T, Hilz MJ.

J Clin Neurophysiol. 2002 Dec;19(6):575-86.

PMID:
12488789
[PubMed - indexed for MEDLINE]
7.

Neurological complications in Fabry disease.

Dütsch M, Hilz MJ.

Rev Med Interne. 2010 Dec;31 Suppl 2:S243-50. doi: 10.1016/S0248-8663(10)70021-7.

PMID:
21211673
[PubMed - indexed for MEDLINE]
8.

Agalsidase alfa: a review of its use in the management of Fabry disease.

Keating GM.

BioDrugs. 2012 Oct 1;26(5):335-54. doi: 10.2165/11209690-000000000-00000. Review.

PMID:
22946754
[PubMed - indexed for MEDLINE]
9.

Twenty-four-month alpha-galactosidase A replacement therapy in Fabry disease has only minimal effects on symptoms and cardiovascular parameters.

Koskenvuo JW, Hartiala JJ, Nuutila P, Kalliokoski R, Viikari JS, Engblom E, Penttinen M, Knuuti J, Mononen I, Kantola IM.

J Inherit Metab Dis. 2008 Jun;31(3):432-41. doi: 10.1007/s10545-008-0848-3. Epub 2008 May 23.

PMID:
18509742
[PubMed - indexed for MEDLINE]
10.

Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R; FOS European Investigators.

J Med Genet. 2005 Mar;42(3):247-52.

PMID:
15744039
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Enzyme replacement therapy with agalsidase alfa in children with Fabry disease.

Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, Santus F, Beck M.

Acta Paediatr. 2007 Jan;96(1):122-7.

PMID:
17187618
[PubMed - indexed for MEDLINE]
12.

Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.

Whitfield PD, Calvin J, Hogg S, O'Driscoll E, Halsall D, Burling K, Maguire G, Wright N, Cox TM, Meikle PJ, Deegan PB.

J Inherit Metab Dis. 2005;28(1):21-33.

PMID:
15702403
[PubMed - indexed for MEDLINE]
13.

Pediatric Fabry disease.

Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, Rosing DR, Robinson C, Schaefer E, Gal A, Dambrosia JM, Garman SC, Brady RO, Schiffmann R.

Pediatrics. 2005 Mar;115(3):e344-55. Epub 2005 Feb 15.

PMID:
15713906
[PubMed - indexed for MEDLINE]
14.

Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa.

Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB.

Heart. 2008 Feb;94(2):153-8. Epub 2007 May 4.

PMID:
17483124
[PubMed - indexed for MEDLINE]
15.

Fabry disease: overall effects of agalsidase alfa treatment.

Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A.

Eur J Clin Invest. 2004 Dec;34(12):838-44.

PMID:
15606727
[PubMed - indexed for MEDLINE]
16.

Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.

Hoffmann B, Beck M, Sunder-Plassmann G, Borsini W, Ricci R, Mehta A; FOS European Investigators.

Clin J Pain. 2007 Jul-Aug;23(6):535-42.

PMID:
17575495
[PubMed - indexed for MEDLINE]
17.

Corneal confocal microscopy: a novel noninvasive means to diagnose neuropathy in patients with Fabry disease.

Tavakoli M, Marshall A, Thompson L, Kenny M, Waldek S, Efron N, Malik RA.

Muscle Nerve. 2009 Dec;40(6):976-84. doi: 10.1002/mus.21383.

PMID:
19902546
[PubMed - indexed for MEDLINE]
18.

Fabry disease.

Toyooka K.

Handb Clin Neurol. 2013;115:629-42. doi: 10.1016/B978-0-444-52902-2.00037-0. Review.

PMID:
23931807
[PubMed - indexed for MEDLINE]
19.

Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.

Üçeyler N, He L, Schönfeld D, Kahn AK, Reiners K, Hilz MJ, Breunig F, Sommer C.

J Peripher Nerv Syst. 2011 Dec;16(4):304-14. doi: 10.1111/j.1529-8027.2011.00365.x.

PMID:
22176145
[PubMed - indexed for MEDLINE]
20.

Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease.

Bierer G, Balfe D, Wilcox WR, Mosenifar Z.

J Inherit Metab Dis. 2006 Aug;29(4):572-9.

PMID:
16817011
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk